Acute ischemic stroke is a clinical emergency and a condition with high morbidity,mortality,and disability.Accurate predictive,diagnostic,and prognostic biomarkers and effective therapeutic targets for acute ischemic ...Acute ischemic stroke is a clinical emergency and a condition with high morbidity,mortality,and disability.Accurate predictive,diagnostic,and prognostic biomarkers and effective therapeutic targets for acute ischemic stroke remain undetermined.With innovations in high-throughput gene sequencing analysis,many aberrantly expressed non-coding RNAs(ncRNAs)in the brain and peripheral blood after acute ischemic stroke have been found in clinical samples and experimental models.Differentially expressed ncRNAs in the post-stroke brain were demonstrated to play vital roles in pathological processes,leading to neuroprotection or deterioration,thus ncRNAs can serve as therapeutic targets in acute ischemic stroke.Moreover,distinctly expressed ncRNAs in the peripheral blood can be used as biomarkers for acute ischemic stroke prediction,diagnosis,and prognosis.In particular,ncRNAs in peripheral immune cells were recently shown to be involved in the peripheral and brain immune response after acute ischemic stroke.In this review,we consolidate the latest progress of research into the roles of ncRNAs(microRNAs,long ncRNAs,and circular RNAs)in the pathological processes of acute ischemic stroke–induced brain damage,as well as the potential of these ncRNAs to act as biomarkers for acute ischemic stroke prediction,diagnosis,and prognosis.Findings from this review will provide novel ideas for the clinical application of ncRNAs in acute ischemic stroke.展开更多
Hepatocellular carcinoma(HCC)is the most common and deadliest subtype of liver cancer worldwide and,therefore,poses an enormous threat to global health.Understanding the molecular mechanisms underlying the development...Hepatocellular carcinoma(HCC)is the most common and deadliest subtype of liver cancer worldwide and,therefore,poses an enormous threat to global health.Understanding the molecular mechanisms underlying the development and progression of HCC is central to improving our clinical approaches.PIWIinteracting RNAs(piRNAs)are a class of small non-coding RNAs that bind to PIWI family proteins to regulate gene expression at transcriptional and posttranscriptional levels.A growing body of work shows that the dysregulation of piRNAs plays a crucial role in the progression of various human cancers.In this editorial,we report on the current knowledge of HCC-associated piRNAs and their potential clinical utility.Based on the editorial by Papadopoulos and Trifylli,on the role and clinical evaluation of exosomal circular RNAs in HCC,we highlight this other emerging class of non-coding RNAs.展开更多
目的构建基于坏死性凋亡相关的长链非编码RNAs(necroptosis-related long non-coding RNAs,NRLs)的肝细胞癌预后模型。方法从TCGA数据库下载肝细胞癌的转录本数据和临床信息。采用LASSO-Cox模型构建预后预测模型,受试者工作特征曲线(rec...目的构建基于坏死性凋亡相关的长链非编码RNAs(necroptosis-related long non-coding RNAs,NRLs)的肝细胞癌预后模型。方法从TCGA数据库下载肝细胞癌的转录本数据和临床信息。采用LASSO-Cox模型构建预后预测模型,受试者工作特征曲线(receiver operating characteristic curve,ROC)和校准曲线评估该模型的预测价值,并进行基因集富集分析(gene set enrichment analysis,GSEA)和免疫浸润分析。qRT-PCR验证4个NRLs在肝细胞癌细胞Huh7和正常肝细胞MIHA中的差异表达。结果本研究构建了基于AL117336.2、MKLN1-AS、FOXD2-AS1、LINC01224等4个NRLs的肝细胞癌风险预后模型。基于训练集构建的风险评分是预后的独立影响因素(HR=1.275,P<0.001)。在训练集中,风险模型预测1、3、5年OS的AUC分别为0.816、0.747、0.752,在测试集中分别为0.713、0.621、0.626,且校准曲线显示模型有较好的一致性。根据中位风险评分将患者划分为高、低风险组,训练集和测试集中高风险组的总存活率均低于低风险组(均P<0.05)。此外,不同风险组中免疫细胞浸润程度和免疫检查点分子的表达差异有统计学意义(均P<0.05)。qRT-PCR检测结果显示,4个NRLs在肝细胞癌细胞Huh7中的表达水平均高于正常肝细胞MIHA(均P<0.05)。结论本研究成功构建了预测肝细胞癌患者预后的NRLs模型,对指导临床治疗具有潜在的价值。展开更多
基金supported by the National Natural Science Foundation of China,Nos.82301486(to SL)and 82071325(to FY)Medjaden Academy&Research Foundation for Young Scientists,No.MJR202310040(to SL)+2 种基金Nanjing Medical University Science and Technique Development,No.NMUB20220060(to SL)Medical Scientific Research Project of Jiangsu Commission of Health,No.ZDA2020019(to JZ)Health China Buchang Zhiyuan Public Welfare Project for Heart and Brain Health,No.HIGHER202102(to QD).
文摘Acute ischemic stroke is a clinical emergency and a condition with high morbidity,mortality,and disability.Accurate predictive,diagnostic,and prognostic biomarkers and effective therapeutic targets for acute ischemic stroke remain undetermined.With innovations in high-throughput gene sequencing analysis,many aberrantly expressed non-coding RNAs(ncRNAs)in the brain and peripheral blood after acute ischemic stroke have been found in clinical samples and experimental models.Differentially expressed ncRNAs in the post-stroke brain were demonstrated to play vital roles in pathological processes,leading to neuroprotection or deterioration,thus ncRNAs can serve as therapeutic targets in acute ischemic stroke.Moreover,distinctly expressed ncRNAs in the peripheral blood can be used as biomarkers for acute ischemic stroke prediction,diagnosis,and prognosis.In particular,ncRNAs in peripheral immune cells were recently shown to be involved in the peripheral and brain immune response after acute ischemic stroke.In this review,we consolidate the latest progress of research into the roles of ncRNAs(microRNAs,long ncRNAs,and circular RNAs)in the pathological processes of acute ischemic stroke–induced brain damage,as well as the potential of these ncRNAs to act as biomarkers for acute ischemic stroke prediction,diagnosis,and prognosis.Findings from this review will provide novel ideas for the clinical application of ncRNAs in acute ischemic stroke.
文摘Hepatocellular carcinoma(HCC)is the most common and deadliest subtype of liver cancer worldwide and,therefore,poses an enormous threat to global health.Understanding the molecular mechanisms underlying the development and progression of HCC is central to improving our clinical approaches.PIWIinteracting RNAs(piRNAs)are a class of small non-coding RNAs that bind to PIWI family proteins to regulate gene expression at transcriptional and posttranscriptional levels.A growing body of work shows that the dysregulation of piRNAs plays a crucial role in the progression of various human cancers.In this editorial,we report on the current knowledge of HCC-associated piRNAs and their potential clinical utility.Based on the editorial by Papadopoulos and Trifylli,on the role and clinical evaluation of exosomal circular RNAs in HCC,we highlight this other emerging class of non-coding RNAs.
文摘目的构建基于坏死性凋亡相关的长链非编码RNAs(necroptosis-related long non-coding RNAs,NRLs)的肝细胞癌预后模型。方法从TCGA数据库下载肝细胞癌的转录本数据和临床信息。采用LASSO-Cox模型构建预后预测模型,受试者工作特征曲线(receiver operating characteristic curve,ROC)和校准曲线评估该模型的预测价值,并进行基因集富集分析(gene set enrichment analysis,GSEA)和免疫浸润分析。qRT-PCR验证4个NRLs在肝细胞癌细胞Huh7和正常肝细胞MIHA中的差异表达。结果本研究构建了基于AL117336.2、MKLN1-AS、FOXD2-AS1、LINC01224等4个NRLs的肝细胞癌风险预后模型。基于训练集构建的风险评分是预后的独立影响因素(HR=1.275,P<0.001)。在训练集中,风险模型预测1、3、5年OS的AUC分别为0.816、0.747、0.752,在测试集中分别为0.713、0.621、0.626,且校准曲线显示模型有较好的一致性。根据中位风险评分将患者划分为高、低风险组,训练集和测试集中高风险组的总存活率均低于低风险组(均P<0.05)。此外,不同风险组中免疫细胞浸润程度和免疫检查点分子的表达差异有统计学意义(均P<0.05)。qRT-PCR检测结果显示,4个NRLs在肝细胞癌细胞Huh7中的表达水平均高于正常肝细胞MIHA(均P<0.05)。结论本研究成功构建了预测肝细胞癌患者预后的NRLs模型,对指导临床治疗具有潜在的价值。
